- |||||||||| Clinical, Review, Journal: Oncogenic Viral Infections Among Iranian Hemodialysis Patients: A Systematic Review. (Pubmed Central) - Jan 14, 2020
Present findings emphasize on requirement to evidence-based practical intervention for better prevention and control of problem. The findings could be used as a scientific evidence for developing related policies and highlighting the future plan of complementary researches.
- |||||||||| The Fusokine FIST15 Enhances Anti-Tumor Immunity Against Murine Osteosarcoma and Prevents Gvhd after Bone Marrow Transplant (World Center Marriott - Palms & Cypress Foyers) - Jan 14, 2020 - Abstract #TCTASTCTCIBMTR2020TCT_1040;
When FIST15 was combined with adoptive NK cell infusion, 100% overall 30-day survival was noted as compared to 50% overall 30-day survival in untreated mice (p < 0.05). FIST15 is a safe and effective biologic against OS when combined with adoptive NK cell infusion after syngeneic BMT, and enhances CD4+ T cells and NK cell subsets while treating lethal GVHD after allogeneic BMT.
- |||||||||| Avastin (bevacizumab) / Roche
Trial completion date, Trial primary completion date: Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma (clinicaltrials.gov) - Jan 14, 2020 P2, N=38, Active, not recruiting, FIST15 is a safe and effective biologic against OS when combined with adoptive NK cell infusion after syngeneic BMT, and enhances CD4+ T cells and NK cell subsets while treating lethal GVHD after allogeneic BMT. Trial completion date: May 2019 --> Jun 2020 | Trial primary completion date: Sep 2018 --> Jun 2020
- |||||||||| imatinib / Generic mfg., sunitinib / Generic mfg.
Trial completion, Stroma: Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT (clinicaltrials.gov) - Jan 14, 2020 P3, N=81, Completed, Trial completion date: May 2019 --> Jun 2020 | Trial primary completion date: Sep 2018 --> Jun 2020 Active, not recruiting --> Completed
- |||||||||| cisplatin / Generic mfg., pemetrexed / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: A Study of Pemetrexed Plus Cisplatin in Patients With Refractory Soft Tissue Sarcoma (clinicaltrials.gov) - Jan 14, 2020 P2, N=37, Active, not recruiting, Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Jun 2020 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Jun 2020
- |||||||||| Trial primary completion date: Symptom Inventory for Gastrointestinal Stromal Tumors (clinicaltrials.gov) - Jan 13, 2020
P=N/A, N=187, Active, not recruiting, These findings set the stage for understanding OS development in dogs and humans, and establish genomic contexts for future comparative analyses. Trial primary completion date: Jul 2019 --> Jul 2020
- |||||||||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca, NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes (clinicaltrials.gov) - Jan 13, 2020 P2, N=62, Active, not recruiting, N=200 --> 120 | Trial completion date: Oct 2026 --> Sep 2025 | Trial primary completion date: Oct 2026 --> Sep 2025 Trial completion date: Aug 2019 --> Aug 2020 | Trial primary completion date: Aug 2019 --> Aug 2020
- |||||||||| Biomarker, Journal: cPLAa correlates with metastasis and poor prognosis of osteosarcoma by facilitating epithelial-mesenchymal transition. (Pubmed Central) - Jan 12, 2020
In conclusion, the study indicated that FER1L4 acted as a tumor suppressor in osteosarcoma via activating PI3K/AKT pathway may be a new prognostic biomarker and potential therapeutic target for osteosarcoma intervention. High cPLAa expression was an independent prognostic biomarker of OS, and cPLAa could promote OS cell invasion via inducing the EMT process, indicating that cPLAa was an independent prognostic biomarker and may be an effective drug target for OS.
- |||||||||| Review, Journal, IO Biomarker: B7-H3 and its role in bone cancers. (Pubmed Central) - Jan 12, 2020
Two clinical trials are conducting on the therapy of osteosarcoma and myeloma using B7-H3 as a target. In conclusion, B7-H3 could be a target of bone cancers.
|